Dear Mrs. DelCarmen:

Please refer to your supplemental new drug application (sNDA) dated and received August 20, 2020, and to your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for TAGRISSO (osimertinib) tablets. This Prior Approval supplemental new drug application provides for a new indication of TAGRISSO as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. In addition the HIGHLIGHTS, Patient Package Insert, and other applicable sections were revised to incorporate relevant information.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

POSTMARKETING COMMITMENT SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

3992-1 Submit the final study report including datasets from the clinical trial ADAURA, titled, “A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-center, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB – IIIA Non small Cell Lung Carcinoma, following Complete Tumor Resection With or Without Adjuvant Chemotherapy (ADAURA)” to provide additional long-term efficacy and safety data that may inform product labeling. The interim study report will contain exploratory DFS analysis and safety data, including datasets (OS analysis will be included only if approximately 94 events in Stage II-IIIA population have been reached). The final study report will contain...

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
report will contain the final OS analysis (approximately 94 events in Stage II-IIIA population have been reached) and safety data including datasets and will contain safety data analyses once follow-up is obtained for all patients who have received osimertinib for three years.

The timetable you submitted on December 16, 2020, states that you will conduct this study according to the following schedule:

- **Final Protocol Submission**: 07/2020 (completed)
- **Interim Report Submission**: 10/2022
- **Trial Completion**: 01/2024
- **Final Report Submission**: 06/2024

A final submitted protocol is one that the FDA has reviewed and commented upon, and you have revised as needed to meet the goal of the study or clinical trial.

Submit clinical protocols to your IND 117879 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled, “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov. Information and Instructions for completing the form can be found at FDA.gov.

---

3 For the most recent version of a guidance, check the FDA guidance web page at [https://www.fda.gov/media/128163/download](https://www.fda.gov/media/128163/download).

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 4719582
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Nataliya Fesenko, Pharm.D., Senior Regulatory Health Project Manager, at (240) 402-6376.

Sincerely,

{See appended electronic signature page}

Harpreet Singh, M.D.
Director
Division of Oncology 2
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

B HARPREE T SINGH
12/18/2020 12:55:43 PM